<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38549864</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Impact of the SARS-CoV-2 Spike Protein on the Innate Immune System: A Review.</ArticleTitle><Pagination><StartPage>e57008</StartPage><MedlinePgn>e57008</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e57008</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.57008</ELocationID><Abstract><AbstractText>The Spike protein enables the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by binding to multiple receptors, including the angiotensin-converting enzyme 2 (ACE2). Scientific studies also indicate that Spike is involved in severe forms of coronavirus disease 2019 (COVID-19), "long-haul COVID diseases" - also known as "long COVID syndromes" or "post-acute sequelae of SARS-CoV-2 infection" (PACS) - or, recently, in adverse reactions to lipid nanoparticle-messenger ribonucleic acid (mRNA) vaccines or other anti-COVID19 products. Numerous mutations, notably within the subunit 1 of Spike (S1), prevent neutralization by antibodies, but more generally, the virus has developed numerous strategies to avoid immune system surveillance, especially type-I interferons (IFN-I). Meanwhile, a "hyperinflammatory" state, named "cytokine storm,"&#xa0;sets in. However, what role does the Spike protein play in the immune escape mechanisms? Can its inflammatory activities affect IFN-I? Does Spike block IFN-I or hijack them for the virus benefits? What are the other potential consequences? This article was written to provide an up-to-date and more general overview of the impact of the Spike protein on the innate immune system and its effectors at the molecular level.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Bocquet-Gar&#xe7;on et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bocquet-Gar&#xe7;on</LastName><ForeName>Annelise</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology, Independent Researcher, B&#xe9;thune, FRA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">innate immune system</Keyword><Keyword MajorTopicYN="N">public awareness about vaccination</Keyword><Keyword MajorTopicYN="N">spike protein and covid-19</Keyword><Keyword MajorTopicYN="N">type-1 interferons</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>3</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38549864</ArticleId><ArticleId IdType="pmc">PMC10973921</ArticleId><ArticleId IdType="doi">10.7759/cureus.57008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Molecular biology of the SARs-CoV-2 spike protein: a review of current knowledge. Zhu C, He G, Yin Q, Zeng L, Ye X, Shi Y, Xu W. J Med Virol. 2021;93:5729&#x2013;5741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427004</ArticleId><ArticleId IdType="pubmed">34125455</ArticleId></ArticleIdList></Reference><Reference><Citation>Structure and mutations of SARS-CoV-2 spike protein: a focused overview. Mehra R, Kepp KP. ACS Infect Dis. 2022;8:29&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">34856799</ArticleId></ArticleIdList></Reference><Reference><Citation>The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Peacock TP, Goldhill DH, Zhou J, et al. Nat Microbiol. 2021;6:899&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">33907312</ArticleId></ArticleIdList></Reference><Reference><Citation>Novel cleavage sites identified in SARS-CoV-2 spike protein reveal mechanism for cathepsin L-facilitated viral infection and treatment strategies. Zhao MM, Zhu Y, Zhang L, et al. Cell Discov. 2022;8:53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167920</ArticleId><ArticleId IdType="pubmed">35668062</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 cell entry beyond the ACE2 receptor. Alipoor SD, Mirsaeidi M. Mol Biol Rep. 2022;49:10715&#x2013;10727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9244107</ArticleId><ArticleId IdType="pubmed">35754059</ArticleId></ArticleIdList></Reference><Reference><Citation>In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Turo&#x148;ov&#xe1; B, Sikora M, Sch&#xfc;rmann C, et al. Science. 2020;370:203&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665311</ArticleId><ArticleId IdType="pubmed">32817270</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 variants, spike mutations and immune escape. Harvey WT, Carabelli AM, Jackson B, et al. Nat Rev Microbiol. 2021;19:409&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8167834</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune escape associated with RBD omicron mutations and SARS-CoV-2 evolution dynamics. Kudriavtsev AV, Vakhrusheva AV, Novos&#x435;letsky VN, Bozdaganyan ME, Shaitan KV, Kirpichnikov MP, Sokolova OS. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9394476</ArticleId><ArticleId IdType="pubmed">35893668</ArticleId></ArticleIdList></Reference><Reference><Citation>Prion-like domains in spike protein of SARS-CoV-2 differ across its variants and enable changes in affinity to ACE2. Tetz G, Tetz V. Microorganisms. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8878784</ArticleId><ArticleId IdType="pubmed">35208734</ArticleId></ArticleIdList></Reference><Reference><Citation>Convergent evolution dynamics of SARS-CoV-2 and HIV surface envelope glycoproteins driven by host cell surface receptors and lipid rafts: lessons for the future. Fantini J, Chahinian H, Yahi N. Int J Mol Sci. 2023;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9915253</ArticleId><ArticleId IdType="pubmed">36768244</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. Bollavaram K, Leeman TH, Lee MW, et al. Protein Sci. 2021;30:1131&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138523</ArticleId><ArticleId IdType="pubmed">33786919</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyloidogenesis of SARS-CoV-2 spike protein. Nystr&#xf6;m S, Hammarstr&#xf6;m P. J Am Chem Soc. 2022;144:8945&#x2013;8950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Competitive cleavage of SARS-CoV-2 spike protein and epithelial sodium channel by plasmin as a potential mechanism for COVID-19 infection. Hou Y, Yu T, Wang T, Ding Y, Cui Y, Nie H. Am J Physiol Lung Cell Mol Physiol. 2022;323:0&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9639761</ArticleId><ArticleId IdType="pubmed">36193902</ArticleId></ArticleIdList></Reference><Reference><Citation>Trypsin enhances SARS-CoV-2 infection by facilitating viral entry. Kim Y, Jang G, Lee D, Kim N, Seon JW, Kim YH, Lee C. Arch Virol. 2022;167:441&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789370</ArticleId><ArticleId IdType="pubmed">35079901</ArticleId></ArticleIdList></Reference><Reference><Citation>TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Zang R, Gomez Castro MF, McCune BT, et al. Sci Immunol. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7285829</ArticleId><ArticleId IdType="pubmed">32404436</ArticleId></ArticleIdList></Reference><Reference><Citation>TMPRSS11D and TMPRSS13 activate the SARS-CoV-2 spike protein. Kishimoto M, Uemura K, Sanaki T, et al. Viruses. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8001073</ArticleId><ArticleId IdType="pubmed">33671076</ArticleId></ArticleIdList></Reference><Reference><Citation>Asymptomatic cases with SARS-CoV-2 infection. Wang Y, Kang H, Liu X, Tong Z. J Med Virol. 2020;92:1401&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267605</ArticleId><ArticleId IdType="pubmed">32383171</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Mehta OP, Bhandari P, Raut A, Kacimi SE, Huy NT. Front Public Health. 2020;8:582932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844320</ArticleId><ArticleId IdType="pubmed">33520910</ArticleId></ArticleIdList></Reference><Reference><Citation>The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies. Zalpoor H, Akbari A, Samei A, et al. Cell Mol Biol Lett. 2022;27:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809072</ArticleId><ArticleId IdType="pubmed">35109786</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients. Pontelli MC, Castro &#xcd;A, Martins RB, et al. J Mol Cell Biol. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384834</ArticleId><ArticleId IdType="pubmed">35451490</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune determinants of COVID-19 disease presentation and severity. Brodin P. Nat Med. 2021;27:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. Hagemann K, Riecken K, Jung JM, et al. Eur J Immunol. 2022;52:1297&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9087393</ArticleId><ArticleId IdType="pubmed">35416291</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation. 2021;44:13&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541099</ArticleId><ArticleId IdType="pubmed">33029758</ArticleId></ArticleIdList></Reference><Reference><Citation>The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19. El-Arif G, Farhat A, Khazaal S, et al. Molecules. 2021;26</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8622307</ArticleId><ArticleId IdType="pubmed">34834033</ArticleId></ArticleIdList></Reference><Reference><Citation>Innate immunity: the first line of defense against SARS-CoV-2. Diamond MS, Kanneganti TD. Nat Immunol. 2022;23:165&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Zhang Q, Bastard P, Liu Z, et al. Science. 2020;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Andreakos E, Abel L, Vinh DC, et al. Nat Immunol. 2022;23:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8524403</ArticleId><ArticleId IdType="pubmed">34667308</ArticleId></ArticleIdList></Reference><Reference><Citation>Activation and evasion of type I interferon responses by SARS-CoV-2. Lei X, Dong X, Ma R, et al. Nat Commun. 2020;11:3810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferon resistance of emerging SARS-CoV-2 variants. Guo K, Barrett BS, Morrison JH, et al. Proc Natl Acad Sci U S A. 2022;119:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9371743</ArticleId><ArticleId IdType="pubmed">35867811</ArticleId></ArticleIdList></Reference><Reference><Citation>Synergism of TNF-&#x3b1; and IFN-&#x3b3; triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Karki R, Sharma BR, Tuladhar S, et al. Cell. 2021;184:149&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674074</ArticleId><ArticleId IdType="pubmed">33278357</ArticleId></ArticleIdList></Reference><Reference><Citation>T cell apoptosis characterizes severe Covid-19 disease. Andr&#xe9; S, Picard M, Cezar R, et al. Cell Death Differ. 2022;29:1486&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782710</ArticleId><ArticleId IdType="pubmed">35066575</ArticleId></ArticleIdList></Reference><Reference><Citation>Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Arunachalam PS, Scott MK, Hagan T, et al. Nature. 2021;596:410&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761119</ArticleId><ArticleId IdType="pubmed">34252919</ArticleId></ArticleIdList></Reference><Reference><Citation>Systemic IL-15, IFN-&#x3b3;, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Bergamaschi C, Terpos E, Rosati M, et al. Cell Rep. 2021;36:109504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8299183</ArticleId><ArticleId IdType="pubmed">34352226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Li C, Lee A, Grigoryan L, et al. Nat Immunol. 2022;23:543&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989677</ArticleId><ArticleId IdType="pubmed">35288714</ArticleId></ArticleIdList></Reference><Reference><Citation>Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Clin Infect Dis. 2023;76:0&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>mRNA vaccines - a new era in vaccinology. Pardi N, Hogan MJ, Porter FW, Weissman D. Nat Rev Drug Discov. 2018;17:261&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Current and future nanoparticle vaccines for COVID-19. Vu MN, Kelly HG, Kent SJ, Wheatley AK. EBioMedicine. 2021;74:103699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8602808</ArticleId><ArticleId IdType="pubmed">34801965</ArticleId></ArticleIdList></Reference><Reference><Citation>Domains and functions of spike protein in Sars-Cov-2 in the context of vaccine design. Xia X. Viruses. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7829931</ArticleId><ArticleId IdType="pubmed">33466921</ArticleId></ArticleIdList></Reference><Reference><Citation>BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Vogel AB, Kanevsky I, Che Y, et al. Nature. 2021;592:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Mart&#xed;nez-Flores D, Zepeda-Cervantes J, Cruz-Res&#xe9;ndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L. Front Immunol. 2021;12:701501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8311925</ArticleId><ArticleId IdType="pubmed">34322129</ArticleId></ArticleIdList></Reference><Reference><Citation>Enhancing the prefusion conformational stability of SARS-CoV-2 spike protein through structure-guided design. Riley TP, Chou HT, Hu R, et al. Front Immunol. 2021;12:660198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100506</ArticleId><ArticleId IdType="pubmed">33968063</ArticleId></ArticleIdList></Reference><Reference><Citation>Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation. Deng T, Li T, Chen G, et al. Vaccine. 2022;40:6839&#x2013;6848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510068</ArticleId><ArticleId IdType="pubmed">36253220</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Bowen JE, Park YJ, Stewart C, et al. Sci Immunol. 2022;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9765460</ArticleId><ArticleId IdType="pubmed">36356052</ArticleId></ArticleIdList></Reference><Reference><Citation>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Wang Z, Schmidt F, Weisblum Y, et al. Nature. 2021;592:616&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8503938</ArticleId><ArticleId IdType="pubmed">33567448</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Anderson EM, Li SH, Awofolaju M, et al. Cell Rep. 2022;41:111496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9578169</ArticleId><ArticleId IdType="pubmed">36261003</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissecting antibodies with regards to linear and conformational epitopes. Forsstr&#xf6;m B, Axn&#xe4;s BB, Rockberg J, Danielsson H, Bohlin A, Uhlen M. PLoS One. 2015;10:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376703</ArticleId><ArticleId IdType="pubmed">25816293</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadly neutralizing antibodies target the coronavirus fusion peptide. Dacon C, Tucker C, Peng L, et al. Science. 2022;377:728&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348754</ArticleId><ArticleId IdType="pubmed">35857439</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutations and evolution of the SARS-CoV-2 spike protein. Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949778</ArticleId><ArticleId IdType="pubmed">35337047</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 variant biology: immune escape, transmission and fitness. Carabelli AM, Peacock TP, Thorne LG, et al. Nat Rev Microbiol. 2023;21:162&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Nunez-Castilla J, Stebliankin V, Baral P, et al. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9318917</ArticleId><ArticleId IdType="pubmed">35891400</ArticleId></ArticleIdList></Reference><Reference><Citation>Predicted structural mimicry of spike receptor-binding motifs from highly pathogenic human coronaviruses. Beaudoin CA, Jamasb AR, Alsulami AF, et al. Comput Struct Biotechnol J. 2021;19:3938&#x2013;3953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249111</ArticleId><ArticleId IdType="pubmed">34234921</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:792&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158893</ArticleId><ArticleId IdType="pubmed">34043615</ArticleId></ArticleIdList></Reference><Reference><Citation>Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Shimizu J, Sasaki T, Koketsu R, et al. Sci Rep. 2022;12:15612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9481526</ArticleId><ArticleId IdType="pubmed">36114224</ArticleId></ArticleIdList></Reference><Reference><Citation>Antibody-mediated cell entry of SARS-CoV-2 [PREPRINT] Md Golam Kibria, Christy L. Lavine, Weichun Tang, et al. bioRxiv. 2023</Citation></Reference><Reference><Citation>Host-viral interactions: role of pattern recognition receptors (PRRs) in human pneumovirus infections. Kolli D, Velayutham TS, Casola A. Pathogens. 2013;2:232&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826451</ArticleId><ArticleId IdType="pubmed">24244872</ArticleId></ArticleIdList></Reference><Reference><Citation>Pattern recognition receptors in health and diseases. Li D, Wu M. Signal Transduct Target Ther. 2021;6:291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8333067</ArticleId><ArticleId IdType="pubmed">34344870</ArticleId></ArticleIdList></Reference><Reference><Citation>Control of adaptive immunity by the innate immune system. Iwasaki A, Medzhitov R. Nat Immunol. 2015;16:343&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507498</ArticleId><ArticleId IdType="pubmed">25789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Host cell-intrinsic innate immune recognition of SARS-CoV-2. Madden EA, Diamond MS. Curr Opin Virol. 2022;52:30&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8580835</ArticleId><ArticleId IdType="pubmed">34814102</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviral infection and interferon response: the virus-host arms race and COVID-19. Liu Q, Chi S, Dmytruk K, Dmytruk O, Tan S. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325157</ArticleId><ArticleId IdType="pubmed">35891331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cytokine storm induced by SARS-CoV-2. Song P, Li W, Xie J, Hou Y, You C. Clin Chim Acta. 2020;509:280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>The cytokine storm and COVID-19. Hu B, Huang S, Yin L. J Med Virol. 2021;93:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 infection: an overview on cytokine storm and related interventions. Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, et al. Virol J. 2022;19:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Zheng M, Karki R, Williams EP, et al. Nat Immunol. 2021;22:829&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 envelope (E) protein binds and activates TLR2 pathway: a novel molecular target for COVID-19 interventions. Plan&#xe8;s R, Bert JB, Tairi S, BenMohamed L, Bahraoui E. Viruses. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146335</ArticleId><ArticleId IdType="pubmed">35632741</ArticleId></ArticleIdList></Reference><Reference><Citation>Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by simvastatin. Qian Y, Lei T, Patel PS, et al. J Virol. 2021;95:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8577385</ArticleId><ArticleId IdType="pubmed">34549987</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. Elife. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein interacts with and activates TLR41. Zhao Y, Kuang M, Li J, et al. Cell Res. 2021;31:818&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Shirato K, Kizaki T. Heliyon. 2021;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887388</ArticleId><ArticleId IdType="pubmed">33644468</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Fontes-Dantas FL, Fernandes GG, Gutman EG, et al. Cell Rep. 2023;42:112189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9935273</ArticleId><ArticleId IdType="pubmed">36857178</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Aboudounya MM, Heads RJ. Mediators Inflamm. 2021;2021:8874339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Ziegler CG, Allon SJ, Nyquist SK, et al. Cell. 2020;181:1016&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry? Scagnolari C, Bitossi C, Viscido A, et al.  http://10.1016/j.cyto.2021.155430. Cytokine. 2021;140:155430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7810030</ArticleId><ArticleId IdType="pubmed">33508651</ArticleId></ArticleIdList></Reference><Reference><Citation>A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. Su S, Jiang S. Signal Transduct Target Ther. 2020;5:71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239689</ArticleId><ArticleId IdType="pubmed">32435059</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 entry genes expression in relation with interferon response in cystic fibrosis patients. Bitossi C, Frasca F, Viscido A, et al. Microorganisms. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824643</ArticleId><ArticleId IdType="pubmed">33401565</ArticleId></ArticleIdList></Reference><Reference><Citation>Amplified RLR signaling activation through an interferon-stimulated gene-endoplasmic reticulum stress-mitochondrial calcium uniporter protein loop. Cheng J, Liao Y, Zhou L, Peng S, Chen H, Yuan Z. Sci Rep. 2016;6:20158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4759556</ArticleId><ArticleId IdType="pubmed">26892273</ArticleId></ArticleIdList></Reference><Reference><Citation>Type I interferon signaling, regulation and gene stimulation in chronic virus infection. Lukhele S, Boukhaled GM, Brooks DG. Semin Immunol. 2019;43:101277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029807</ArticleId><ArticleId IdType="pubmed">31155227</ArticleId></ArticleIdList></Reference><Reference><Citation>Large screening identifies ACE2 positively correlates with NF-&#x3ba;B signaling activity and targeting NF-&#x3ba;B signaling drugs suppress ACE2 levels. Yan M, Dong Y, Bo X, Cheng Y, Cheng J. Front Pharmacol. 2021;12:771555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8639591</ArticleId><ArticleId IdType="pubmed">34867400</ArticleId></ArticleIdList></Reference><Reference><Citation>Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes. Yao Y, Subedi K, Liu T, et al. Cell Discov. 2022;8:89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9462622</ArticleId><ArticleId IdType="pubmed">36085197</ArticleId></ArticleIdList></Reference><Reference><Citation>A new storm on the horizon in COVID-19: bradykinin-induced vascular complications. McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC. Vascul Pharmacol. 2021;137:106826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834250</ArticleId><ArticleId IdType="pubmed">33358968</ArticleId></ArticleIdList></Reference><Reference><Citation>A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Garvin MR, Alvarez C, Miller JI, et al. Elife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410499</ArticleId><ArticleId IdType="pubmed">32633718</ArticleId></ArticleIdList></Reference><Reference><Citation>The interplay between angiotensin II, TLR4 and hypertension. Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. Pharmacol Res. 2017;120:88&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330785</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity. Petruk G, Puthia M, Petrlova J, et al. J Mol Cell Biol. 2020;12:916&#x2013;932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799037</ArticleId><ArticleId IdType="pubmed">33295606</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein aggregation is triggered by bacterial lipopolysaccharide. Petrlova J, Samsudin F, Bond PJ, Schmidtchen A. FEBS Lett. 2022;596:2566&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538650</ArticleId><ArticleId IdType="pubmed">36050806</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade. Samsudin F, Raghuvamsi P, Petruk G, et al. J Mol Cell Biol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940780</ArticleId><ArticleId IdType="pubmed">36240490</ArticleId></ArticleIdList></Reference><Reference><Citation>Amyloid and hydrogel formation of a peptide sequence from a coronavirus spike protein. Castelletto V, Hamley IW. ACS Nano. 2022;16:1857&#x2013;1867.</Citation></Reference><Reference><Citation>SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties. Frank MG, Nguyen KH, Ball JB, et al. Brain Behav Immun. 2022;100:267&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667429</ArticleId><ArticleId IdType="pubmed">34915155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitogen activated protein kinase (MAPK) activation, p53, and autophagy inhibition characterize the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein induced neurotoxicity. Kyriakopoulos AM, Nigh G, McCullough PA, Seneff S. Cureus. 2022;14:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9733976</ArticleId><ArticleId IdType="pubmed">36514706</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike protein S2 subunit modulates &#x3b3;-secretase and enhances amyloid-&#x3b2; production in COVID-19 neuropathy. Ma G, Zhang DF, Zou QC, et al. Cell Discov. 2022;8:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9524330</ArticleId><ArticleId IdType="pubmed">36180433</ArticleId></ArticleIdList></Reference><Reference><Citation>The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection. Nuovo GJ, Suster D, Sawant D, Mishra A, Michaille JJ, Tili E. Ann Diagn Pathol. 2022;61:152057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9616485</ArticleId><ArticleId IdType="pubmed">36334414</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Idrees D, Kumar V. Biochem Biophys Res Commun. 2021;554:94&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988450</ArticleId><ArticleId IdType="pubmed">33789211</ArticleId></ArticleIdList></Reference><Reference><Citation>The Effects of A&#x3b2;(1-42) binding to the SARS-CoV-2 Spike protein S1 subunit and angiotensin-converting enzyme 2. Hsu JT, Tien CF, Yu GY, et al. Int J Mol Sci. 2021;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8347908</ArticleId><ArticleId IdType="pubmed">34360989</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomic deletion of TLR2 induces aggravated white matter damage and deteriorated neurobehavioral functions in mouse models of Alzheimer's disease. Zhou C, Sun X, Hu Y, et al. Aging (Albany NY) 2019;11:7257&#x2013;7273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6756907</ArticleId><ArticleId IdType="pubmed">31509519</ArticleId></ArticleIdList></Reference><Reference><Citation>Beta amyloid aggregates induce sensitised TLR4 signalling causing long-term potentiation deficit and rat&#xa0;neuronal cell death. Hughes C, Choi ML, Yi JH, et al. Commun Biol. 2020;3:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028984</ArticleId><ArticleId IdType="pubmed">32071389</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential health risks of mRNA-based vaccine therapy: A hypothesis. Acevedo-Whitehouse K, Bruno R. Med Hypotheses. 2023;171:111015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9876036</ArticleId><ArticleId IdType="pubmed">36718314</ArticleId></ArticleIdList></Reference><Reference><Citation>ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Liu G, Lee JH, Parker ZM, et al. Nat Microbiol. 2021;6:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103894</ArticleId><ArticleId IdType="pubmed">33727702</ArticleId></ArticleIdList></Reference><Reference><Citation>ISG15 in antiviral immunity and beyond. Perng YC, Lenschow DJ. Nat Rev Microbiol. 2018;16:423&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097117</ArticleId><ArticleId IdType="pubmed">29769653</ArticleId></ArticleIdList></Reference><Reference><Citation>HERC5 and the ISGylation pathway: critical modulators of the antiviral immune response. Mathieu NA, Paparisto E, Barr SD, Spratt DE. Viruses. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8228270</ArticleId><ArticleId IdType="pubmed">34207696</ArticleId></ArticleIdList></Reference><Reference><Citation>Human intracellular ISG15 prevents interferon-&#x3b1;/&#x3b2; over-amplification and auto-inflammation. Zhang X, Bogunovic D, Payelle-Brogard B, et al. Nature. 2015;517:89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4303590</ArticleId><ArticleId IdType="pubmed">25307056</ArticleId></ArticleIdList></Reference><Reference><Citation>USP18 - a multifunctional component in the interferon response. Basters A, Knobeloch KP, Fritz G. Biosci Rep. 2018;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6240716</ArticleId><ArticleId IdType="pubmed">30126853</ArticleId></ArticleIdList></Reference><Reference><Citation>Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification. Park JH, Yang SW, Park JM, et al. Nat Commun. 2016;7:12513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4996943</ArticleId><ArticleId IdType="pubmed">27545325</ArticleId></ArticleIdList></Reference><Reference><Citation>Extracellular ISG15 Signals Cytokine Secretion through the LFA-1 Integrin Receptor. Swaim CD, Scott AF, Canadeo LA, Huibregtse JM. Mol Cell. 2017;68(3):581&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5690536</ArticleId><ArticleId IdType="pubmed">29100055</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA-1273. Nakayama T, Sawada A, Ito T. Microbiol Immunol. 2023;67:120&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878178</ArticleId><ArticleId IdType="pubmed">36480238</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. Miyashita Y, Yoshida T, Takagi Y, et al. NPJ Vaccines. 2022;7:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8826357</ArticleId><ArticleId IdType="pubmed">35136071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatal multisystem inflammatory syndrome in adult after SARS-CoV-2 natural infection and COVID-19 vaccination. Grome HN, Threlkeld M, Threlkeld S, et al. Emerg Infect Dis. 2021;27:2914&#x2013;2918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544993</ArticleId><ArticleId IdType="pubmed">34586059</ArticleId></ArticleIdList></Reference><Reference><Citation>Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V) Nune A, Iyengar KP, Goddard C, Ahmed AE. BMJ Case Rep. 2021;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323360</ArticleId><ArticleId IdType="pubmed">34326117</ArticleId></ArticleIdList></Reference><Reference><Citation>Multisystem inflammatory syndrome in adult after first dose of mRNA vaccine. Miyazato Y, Yamamoto K, Yamada G, et al. Emerg Infect Dis. 2022;28:870&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8962876</ArticleId><ArticleId IdType="pubmed">35148495</ArticleId></ArticleIdList></Reference><Reference><Citation>Multisystem inflammatory syndrome in a 12-year-old boy after mRNA-SARS-CoV-2 vaccination. Abdelgalil AA, Saeedi FA. Pediatr Infect Dis J. 2022;41:0&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828311</ArticleId><ArticleId IdType="pubmed">34955518</ArticleId></ArticleIdList></Reference><Reference><Citation>A case of multisystem inflammatory syndrome in a 12-year-old male after COVID-19 mRNA vaccine. Yal&#xe7;inkaya R, &#xd6;z FN, Polat M, et al. Pediatr Infect Dis J. 2022;41:0&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828314</ArticleId><ArticleId IdType="pubmed">34978781</ArticleId></ArticleIdList></Reference><Reference><Citation>The CXCL10/CXCR3 axis and cardiac inflammation: implications for immunotherapy to treat infectious and noninfectious diseases of the heart. Altara R, Mallat Z, Booz GW, Zouein FA. J Immunol Res. 2016;2016:4396368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5066021</ArticleId><ArticleId IdType="pubmed">27795961</ArticleId></ArticleIdList></Reference><Reference><Citation>Increased interleukin 18-dependent immune responses are associated with myopericarditis after COVID-19 mRNA vaccination. Won T, Gilotra NA, Wood MK, et al. Front Immunol. 2022;13:851620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894592</ArticleId><ArticleId IdType="pubmed">35251049</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccination-associated myocarditis and myocardial injury. Altman NL, Berning AA, Mann SC, et al. Circ Res. 2023;132:1338&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10171307</ArticleId><ArticleId IdType="pubmed">37167355</ArticleId></ArticleIdList></Reference><Reference><Citation>Multidisciplinary diagnostic approach for fulminant myocarditis related to coronavirus disease 2019 messenger RNA vaccines: a case report. Fujii M, Toba T, Fukuyama Y, Tjan LH, Mori Y, Hirata KI. Eur Heart J Case Rep. 2023;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933941</ArticleId><ArticleId IdType="pubmed">36819885</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferon-stimulated genes and their antiviral effector functions. Schoggins JW, Rice CM. Curr Opin Virol. 2011;1:519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274382</ArticleId><ArticleId IdType="pubmed">22328912</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike protein suppresses ACE2 and type I interferon expression in primary cells from macaque lung bronchoalveolar lavage. Sui Y, Li J, Venzon DJ, Berzofsky JA. Front Immunol. 2021;12:658428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213020</ArticleId><ArticleId IdType="pubmed">34149696</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike antagonizes innate antiviral immunity by targeting interferon regulatory factor 3. Freitas RS, Crum TF, Parvatiyar K. Front Cell Infect Microbiol. 2021;11:789462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8785962</ArticleId><ArticleId IdType="pubmed">35083167</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteasome inhibitors as a possible therapy for SARS-CoV-2. Longhitano L, Tibullo D, Giallongo C, et al. Int J Mol Sci. 2020;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279248</ArticleId><ArticleId IdType="pubmed">32443911</ArticleId></ArticleIdList></Reference><Reference><Citation>Elucidating host cell response pathways and repurposing therapeutics for SARS-CoV-2 and other coronaviruses. Shen Z, Halberg A, Fong JY, et al. Sci Rep. 2022;12:18811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637228</ArticleId><ArticleId IdType="pubmed">36335206</ArticleId></ArticleIdList></Reference><Reference><Citation>A practical review of proteasome pharmacology. Thibaudeau TA, Smith DM. Pharmacol Rev. 2019;71:170&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6423620</ArticleId><ArticleId IdType="pubmed">30867233</ArticleId></ArticleIdList></Reference><Reference><Citation>Syncytia formation by SARS-CoV-2-infected cells. Buchrieser J, Dufloo J, Hubert M, et al. EMBO J. 2020;39:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646020</ArticleId><ArticleId IdType="pubmed">33051876</ArticleId></ArticleIdList></Reference><Reference><Citation>D614G substitution of SARS-CoV-2 Spike protein increases syncytium formation and virus titer via enhanced furin-mediated spike cleavage. Cheng YW, Chao TL, Li CL, et al. mBio. 2021;12:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8406174</ArticleId><ArticleId IdType="pubmed">34311586</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination. Zhang Z, Zheng Y, Niu Z, et al. Cell Death Differ. 2021;28:2765&#x2013;2777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056997</ArticleId><ArticleId IdType="pubmed">33879858</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Alpha, Beta, and Delta variants display enhanced Spike-mediated syncytia formation. Rajah MM, Hubert M, Bishop E, et al. EMBO J. 2021;40:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646911</ArticleId><ArticleId IdType="pubmed">34601723</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapid quantitative monitoring of SARS-CoV-2 spike protein-mediated syncytia formation using split NanoLuc. Wang H, Guo S, Yang H. J Med Virol. 2022;94:6073&#x2013;6077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538440</ArticleId><ArticleId IdType="pubmed">35940856</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response. Liu X, Wei L, Xu F, et al. Sci Signal. 2022;15:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">35412852</ArticleId></ArticleIdList></Reference><Reference><Citation>IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro. Prelli Bozzo C, Nchioua R, Volcic M, et al. Nat Commun. 2021;12:4584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319209</ArticleId><ArticleId IdType="pubmed">34321474</ArticleId></ArticleIdList></Reference><Reference><Citation>Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques. Hoang TN, Viox EG, Upadhyay AA, et al. bioRxiv. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10936760</ArticleId><ArticleId IdType="pubmed">37506197</ArticleId></ArticleIdList></Reference><Reference><Citation>The P681H mutation in the Spike glycoprotein of the alpha variant of SARS-CoV-2 escapes IFITM restriction and is necessary for type I interferon resistance. Lista MJ, Winstone H, Wilson HD, et al. J Virol. 2022;96:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749455</ArticleId><ArticleId IdType="pubmed">36350154</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 evolution influences GBP and IFITM sensitivity. Mesner D, Reuschl AK, Whelan MV, et al. Proc Natl Acad Sci U S A. 2023;120:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945951</ArticleId><ArticleId IdType="pubmed">36693093</ArticleId></ArticleIdList></Reference><Reference><Citation>Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1. Nchioua R, Schundner A, Klute S, et al. Life Sci Alliance. 2023;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10053418</ArticleId><ArticleId IdType="pubmed">36977594</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells. Gori Savellini G, Anichini G, Cusi MG. Virus Res. 2023;332:199134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10191105</ArticleId><ArticleId IdType="pubmed">37192725</ArticleId></ArticleIdList></Reference><Reference><Citation>TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. Nat Immunol. 2008;9:361&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112825</ArticleId><ArticleId IdType="pubmed">18297073</ArticleId></ArticleIdList></Reference><Reference><Citation>A comparative study of spike protein of SARS-CoV-2 and its variant Omicron (B.1.1.529) on some immune characteristics. Li X, Li W, Liu Z, et al. Sci Rep. 2022;12:17058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9554390</ArticleId><ArticleId IdType="pubmed">36224298</ArticleId></ArticleIdList></Reference><Reference><Citation>Dissociation of TRIF bias and adjuvanticity. Richard K, Perkins DJ, Harberts EM, et al. Vaccine. 2020;38:4298&#x2013;4308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302928</ArticleId><ArticleId IdType="pubmed">32389496</ArticleId></ArticleIdList></Reference><Reference><Citation>TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Bortolotti D, Gentili V, Rizzo S, et al. Microorganisms. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465566</ArticleId><ArticleId IdType="pubmed">34576716</ArticleId></ArticleIdList></Reference><Reference><Citation>Activation of TLR4 by viral glycoproteins: a double-edged sword? Halajian EA, LeBlanc EV, Gee K, Colpitts CC. Front Microbiol. 2022;13:1007081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557975</ArticleId><ArticleId IdType="pubmed">36246240</ArticleId></ArticleIdList></Reference><Reference><Citation>The increased amyloidogenicity of Spike RBD and pH-dependent binding to ACE2 may contribute to the transmissibility and pathogenic properties of SARS-CoV-2 omicron as suggested by in silico study. Aksenova AY, Likhachev IV, Grishin SY, Galzitskaya OV. Int J Mol Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9655063</ArticleId><ArticleId IdType="pubmed">36362302</ArticleId></ArticleIdList></Reference><Reference><Citation>Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Meng B, Abdullahi A, Ferreira IA, et al. Nature. 2022;603:706&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Willett BJ, Grove J, MacLean OA, et al. Nat Microbiol. 2022;7:1161&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Hu B, Chan JF, Liu H, et al. Emerg Microbes Infect. 2022;11:2275&#x2013;2287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9542985</ArticleId><ArticleId IdType="pubmed">36039901</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 omicron specific mutations affecting infectivity, fusogenicity, and partial TMPRSS2-independency. Strobelt R, Broennimann K, Adler J, Shaul Y. Viruses. 2023;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10223509</ArticleId><ArticleId IdType="pubmed">37243215</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models. Mykytyn AZ, Breugem TI, Geurts MH, et al. J Virol. 2023;97:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10506477</ArticleId><ArticleId IdType="pubmed">37555660</ArticleId></ArticleIdList></Reference><Reference><Citation>Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip variants [PREPRINT] Qu P, Xu K, Faraone JN, et al. bioRxiv. 2023</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10872432</ArticleId><ArticleId IdType="pubmed">38194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Control of SARS-CoV-2 infection by MT1-MMP-mediated shedding of ACE2. Guo X, Cao J, Cai JP, et al. Nat Commun. 2022;13:7907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780620</ArticleId><ArticleId IdType="pubmed">36564389</ArticleId></ArticleIdList></Reference><Reference><Citation>Altered host protease determinants for SARS-CoV-2 Omicron. Chan JF, Huang X, Hu B, et al. Sci Adv. 2023;9:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9858505</ArticleId><ArticleId IdType="pubmed">36662861</ArticleId></ArticleIdList></Reference><Reference><Citation>S protein, ACE2 and host cell proteases in SARS-CoV-2 cell entry and infectivity; is soluble ACE2 a two blade sword? a narrative review. Nejat R, Torshizi MF, Najafi DJ. Vaccines (Basel) 2023;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968219</ArticleId><ArticleId IdType="pubmed">36851081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Zhao MM, Yang WL, Yang FY, et al. Signal Transduct Target Ther. 2021;6:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997800</ArticleId><ArticleId IdType="pubmed">33774649</ArticleId></ArticleIdList></Reference><Reference><Citation>Variation of proteolytic cleavage sites towards the N-terminal end of the s2 subunit of the novel SARS-CoV-2 Omicron sublineage BA.2.12.1. Schilling NA, Kalbacher H, Burster T. Molecules. 2022;27</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9506045</ArticleId><ArticleId IdType="pubmed">36144551</ArticleId></ArticleIdList></Reference><Reference><Citation>Occurrence of a novel cleavage site for cathepsin G adjacent to the polybasic sequence within the proteolytically sensitive activation loop of the SARS-CoV-2 Omicron variant: the amino acid substitution N679K and P681H of the spike protein. Mustafa Z, Kalbacher H, Burster T. PLoS One. 2022;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015119</ArticleId><ArticleId IdType="pubmed">35436320</ArticleId></ArticleIdList></Reference><Reference><Citation>A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial-mesenchymal transition. Zhao YF, Han ML, Xiong YJ, et al. Acta Pharmacol Sin. 2018;39:1034&#x2013;1047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6256272</ArticleId><ArticleId IdType="pubmed">29219949</ArticleId></ArticleIdList></Reference><Reference><Citation>Upregulation of miRNA-200c during disease progression in COVID-19 patients. van de Sand L, Bra&#xdf; P, Gregorius J, et al. J Clin Med. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821078</ArticleId><ArticleId IdType="pubmed">36615083</ArticleId></ArticleIdList></Reference><Reference><Citation>MiR-200c-3p expression may be associated with worsening of the clinical course of patients with COVID-19. Pimenta R, Viana NI, Dos Santos GA, et al. Mol Biol Res Commun. 2021;10:141&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340313</ArticleId><ArticleId IdType="pubmed">34476267</ArticleId></ArticleIdList></Reference><Reference><Citation>Upregulated miR-200c is associated with downregulation of the functional receptor for severe acute respiratory syndrome coronavirus 2 ACE2 in individuals with obesity. Bellae Papannarao J, Schwenke DO, Manning P, Katare R. Int J Obes (Lond) 2022;46:238&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8499608</ArticleId><ArticleId IdType="pubmed">34625660</ArticleId></ArticleIdList></Reference><Reference><Citation>miRNA-200c-3p is crucial in acute respiratory distress syndrome. Liu Q, Du J, Yu X, et al. Cell Discov. 2017;3:17021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485385</ArticleId><ArticleId IdType="pubmed">28690868</ArticleId></ArticleIdList></Reference><Reference><Citation>Evaluation of miR-200c-3p and miR-421-5p levels during immune responses in the admitted and recovered COVID-19 subjects. Abdolahi S, Hosseini M, Rezaei R, et al. Infect Genet Evol. 2022;98:105207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8730736</ArticleId><ArticleId IdType="pubmed">34999004</ArticleId></ArticleIdList></Reference><Reference><Citation>MicroRNA-200c-targeted contactin 1 facilitates the replication of influenza A virus by accelerating the degradation of MAVS. Xu S, Han L, Wei Y, et al. PLoS Pathog. 2022;18:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8849533</ArticleId><ArticleId IdType="pubmed">35171955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell-based receptor discovery identifies host factors specifically targeted by the SARS CoV-2 spike. Husain B, Yuen K, Sun D, Cao S, Payandeh J, Martinez-Martin N. Commun Biol. 2022;5:788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9355963</ArticleId><ArticleId IdType="pubmed">35931765</ArticleId></ArticleIdList></Reference><Reference><Citation>BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Sahin U, Muik A, Vogler I, et al. Nature. 2021;595:572&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">34044428</ArticleId></ArticleIdList></Reference><Reference><Citation>Stability of SARS-CoV-2-encoded proteins and their antibody levels correlate with interleukin 6 in COVID-19 patients. Li W, Kitsios GD, Bain W, et al. mSystems. 2022;7:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9238396</ArticleId><ArticleId IdType="pubmed">35582921</ArticleId></ArticleIdList></Reference><Reference><Citation>Influence of protein fold stability on immunogenicity and its implications for vaccine design. Scheiblhofer S, Laimer J, Machado Y, Weiss R, Thalhamer J. Expert Rev Vaccines. 2017;16:479&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5490637</ArticleId><ArticleId IdType="pubmed">28290225</ArticleId></ArticleIdList></Reference><Reference><Citation>Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Sato M, Suemori H, Hata N, et al.  https://doi.org/10.1016/S1074-7613(00)00053-4. Immunity. 2000;13:539&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">11070172</ArticleId></ArticleIdList></Reference><Reference><Citation>IRF7: role and regulation in immunity and autoimmunity. Ma W, Huang G, Wang Z, Wang L, Gao Q. Front Immunol. 2023;14:1236923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10449649</ArticleId><ArticleId IdType="pubmed">37638030</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferon regulatory factor 7 in inflammation, cancer and infection. Qing F, Liu Z. Front Immunol. 2023;14:1190841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10213216</ArticleId><ArticleId IdType="pubmed">37251373</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike targets USP33-IRF9 axis via exosomal miR-148a to activate human microglia. Mishra R, Banerjea AC. Front Immunol. 2021;12:656700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8079643</ArticleId><ArticleId IdType="pubmed">33936086</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview of microRNA biogenesis, mechanisms of actions, and circulation. O'Brien J, Hayder H, Zayed Y, Peng C. Front Endocrinol (Lausanne) 2018;9:402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085463</ArticleId><ArticleId IdType="pubmed">30123182</ArticleId></ArticleIdList></Reference><Reference><Citation>Burning down the house: IRF7 makes the difference for microglia. Hagemeyer N, Prinz M. EMBO J. 2014;33:2885&#x2013;2886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282636</ArticleId><ArticleId IdType="pubmed">25394636</ArticleId></ArticleIdList></Reference><Reference><Citation>Dual role of p53 in innate antiviral immunity. Rivas C, Aaronson SA, Munoz-Fontela C. Viruses. 2010;2:298&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185551</ArticleId><ArticleId IdType="pubmed">21994612</ArticleId></ArticleIdList></Reference><Reference><Citation>Strategies to target ISG15 and USP18 toward therapeutic applications. Jim&#xe9;nez Fern&#xe1;ndez D, Hess S, Knobeloch KP. Front Chem. 2019;7:923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6985271</ArticleId><ArticleId IdType="pubmed">32039148</ArticleId></ArticleIdList></Reference><Reference><Citation>A molecular switch from STAT2-IRF9 to ISGF3 underlies interferon-induced gene transcription. Platanitis E, Demiroz D, Schneller A, et al. Nat Commun. 2019;10:2921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6606597</ArticleId><ArticleId IdType="pubmed">31266943</ArticleId></ArticleIdList></Reference><Reference><Citation>The type I interferonopathies: 10 years on. Crow YJ, Stetson DB. Nat Rev Immunol. 2022;22:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8527296</ArticleId><ArticleId IdType="pubmed">34671122</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferon regulatory factor 9 structure and regulation. Paul A, Tang TH, Ng SK. Front Immunol. 2018;9:1831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095977</ArticleId><ArticleId IdType="pubmed">30147694</ArticleId></ArticleIdList></Reference><Reference><Citation>P53 deficiency potentiates LPS-Induced acute lung injury in vivo. Uddin MA, Akhter MS, Kubra KT, Barabutis N. Curr Res Physiol. 2020;3:30&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386399</ArticleId><ArticleId IdType="pubmed">32724900</ArticleId></ArticleIdList></Reference><Reference><Citation>S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study. Singh N, Bharara Singh A. Transl Oncol. 2020;13:100814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7324311</ArticleId><ArticleId IdType="pubmed">32619819</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. de Gonzalo-Calvo D, Ben&#xed;tez ID, Pinilla L, et al. Transl Res. 2021;236:147&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8149473</ArticleId><ArticleId IdType="pubmed">34048985</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating microRNAs as emerging regulators of COVID-19. Liang Y, Fang D, Gao X, et al. Theranostics. 2023;13:125&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9800721</ArticleId><ArticleId IdType="pubmed">36593971</ArticleId></ArticleIdList></Reference><Reference><Citation>miR-148a affects polarization of THP-1-derived macrophages and reduces recruitment of tumor-associated macrophages via targeting SIRP&#x3b1;. Ma D, Zhang Y, Chen G, Yan J. Cancer Manag Res. 2020;12:8067&#x2013;8077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490441</ArticleId><ArticleId IdType="pubmed">32982404</ArticleId></ArticleIdList></Reference><Reference><Citation>miR-148a-3p mediates notch signaling to promote the differentiation and M1 activation of macrophages. Huang F, Zhao JL, Wang L, et al. Front Immunol. 2017;8:1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650608</ArticleId><ArticleId IdType="pubmed">29085372</ArticleId></ArticleIdList></Reference><Reference><Citation>NOTCH signaling in COVID-19: a central hub controlling genes, proteins, and cells that mediate SARS-CoV-2 entry, the inflammatory response, and lung regeneration. Baindara P, Sarker MB, Earhart AP, Mandal SM, Schrum AG. Front Cell Infect Microbiol. 2022;12:928704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9386183</ArticleId><ArticleId IdType="pubmed">35992174</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x3b3;-Secretase in Alzheimer's disease. Hur JY. Exp Mol Med. 2022;54:433&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9076685</ArticleId><ArticleId IdType="pubmed">35396575</ArticleId></ArticleIdList></Reference><Reference><Citation>Modulation of notch signaling pathway by bioactive dietary agents. Kiesel VA, Stan SD. Int J Mol Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8998406</ArticleId><ArticleId IdType="pubmed">35408894</ArticleId></ArticleIdList></Reference><Reference><Citation>Conserved MicroRNAs in human nasopharynx tissue samples from swabs are differentially expressed in response to SARS-CoV-2. Eichmeier A, Kiss T, Kocanova M, Hakalova E, Spetik M, Cechova J, Tichy B. Genes (Basel) 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8871708</ArticleId><ArticleId IdType="pubmed">35205390</ArticleId></ArticleIdList></Reference><Reference><Citation>The effects of secretory IgA in the mucosal immune system. Li Y, Jin L, Chen T. Biomed Res Int. 2020;2020:2032057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970489</ArticleId><ArticleId IdType="pubmed">31998782</ArticleId></ArticleIdList></Reference><Reference><Citation>miR&#x2011;148a modulates the viability, migration and invasion of oral squamous cell carcinoma cells by regulating HLA&#x2011;G expression. Zhang Y, Jin X, Wang J. Mol Med Rep. 2019;20:795&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580030</ArticleId><ArticleId IdType="pubmed">31180532</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA-G expressing immune cells in immune mediated diseases. Contini P, Murdaca G, Puppo F, Negrini S. Front Immunol. 2020;11:1613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484697</ArticleId><ArticleId IdType="pubmed">32983083</ArticleId></ArticleIdList></Reference><Reference><Citation>Induction of pulmonary HLA-G expression by SARS-CoV-2 infection. Seliger B, Jasinski-Bergner S, Massa C, et al. Cell Mol Life Sci. 2022;79:582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9637071</ArticleId><ArticleId IdType="pubmed">36334153</ArticleId></ArticleIdList></Reference><Reference><Citation>Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. Cell Mol Life Sci. 2011;68:369&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3021195</ArticleId><ArticleId IdType="pubmed">21107637</ArticleId></ArticleIdList></Reference><Reference><Citation>Interleukin 10 induces the expression of membrane-bound HLA- G and the production of soluble HLA-G on HeLa CCL-2 cells. Hasanah N, Mintaroem K, Fitri LE, Noorhamdani N. Open Access Maced J Med Sci. 2019;7:3554&#x2013;3558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986524</ArticleId><ArticleId IdType="pubmed">32010375</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA-G genotype/expression/disease association studies: success, hurdles, and perspectives. Amodio G, Gregori S. Front Immunol. 2020;11:1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360675</ArticleId><ArticleId IdType="pubmed">32733439</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 coronavirus Spike protein-induced apoptosis, inflammatory, and oxidative stress responses in THP-1-like-macrophages: potential role of angiotensin-converting enzyme inhibitor (perindopril) Barhoumi T, Alghanem B, Shaibah H, et al. Front Immunol. 2021;12:728896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488399</ArticleId><ArticleId IdType="pubmed">34616396</ArticleId></ArticleIdList></Reference><Reference><Citation>Metformin suppresses monocyte immunometabolic activation by SARS-CoV-2 Spike protein subunit 1. Cory TJ, Emmons RS, Yarbro JR, Davis KL, Pence BD. Front Immunol. 2021;12:733921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8631967</ArticleId><ArticleId IdType="pubmed">34858397</ArticleId></ArticleIdList></Reference><Reference><Citation>Biology and therapeutic potential of interleukin-10. Saraiva M, Vieira P, O'Garra A. J Exp Med. 2020;217</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7037253</ArticleId><ArticleId IdType="pubmed">31611251</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 uses CD4 to infect T helper lymphocytes. Brunetti NS, Davanzo GG, de Moraes D, et al. Elife. 2023;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10390044</ArticleId><ArticleId IdType="pubmed">37523305</ArticleId></ArticleIdList></Reference><Reference><Citation>miR-148a promotes plasma cell differentiation and targets the germinal center transcription factors Mitf and Bach2. Porstner M, Winkelmann R, Daum P, et al. Eur J Immunol. 2015;45:1206&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pubmed">25678371</ArticleId></ArticleIdList></Reference><Reference><Citation>miR-148a controls metabolic programming and survival of mature CD19-negative plasma cells in mice. Pracht K, Meinzinger J, Schulz SR, et al. Eur J Immunol. 2021;51:1089&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">33336366</ArticleId></ArticleIdList></Reference><Reference><Citation>miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim. Haftmann C, Stittrich AB, Zimmermann J, et al. Eur J Immunol. 2015;45:1192&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4406154</ArticleId><ArticleId IdType="pubmed">25486906</ArticleId></ArticleIdList></Reference><Reference><Citation>MiR-148a deletion protects from bone loss in physiological and estrogen-deficient mice by targeting NRP1. Pan B, Zheng L, Liu S, et al. Cell Death Discov. 2022;8:470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9708754</ArticleId><ArticleId IdType="pubmed">36446758</ArticleId></ArticleIdList></Reference><Reference><Citation>MicroRNA-148a/b-3p regulates angiogenesis by targeting neuropilin-1 in endothelial cells. Kim H, Ko Y, Park H, et al. Exp Mol Med. 2019;51:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853980</ArticleId><ArticleId IdType="pubmed">31723119</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropilin-1 is a host factor for SARS-CoV-2 infection. Daly JL, Simonetti B, Klein K, et al. Science. 2020;370:861&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612957</ArticleId><ArticleId IdType="pubmed">33082294</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus-receptor interactions of SARS-CoV-2 spikereceptor-binding domain and human neuropilin-1 b1 domain. Alnomasy SF. Saudi J Biol Sci. 2021;28:3926&#x2013;3928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8032480</ArticleId><ArticleId IdType="pubmed">33850424</ArticleId></ArticleIdList></Reference><Reference><Citation>The role of neuropilin-1 (NRP-1) in SARS-CoV-2 infection: review. Gudowska-Sawczuk M, Mroczko B. J Clin Med. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267897</ArticleId><ArticleId IdType="pubmed">34202613</ArticleId></ArticleIdList></Reference><Reference><Citation>Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy. Roy S, Bag AK, Singh RK, Talmadge JE, Batra SK, Datta K. Front Immunol. 2017;8:1228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641316</ArticleId><ArticleId IdType="pubmed">29067024</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropilin-1 Acts as a Receptor for Complement Split Products. Claire Battin, Annika De Sousa Linhares, Wolfgang Paster, David E. Isenman, Markus Wahrmann, Judith Leitner, Gerhard J. https://doi.org/10.3389/fimmu.2019.02209 Front. Immunol. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753332</ArticleId><ArticleId IdType="pubmed">31572401</ArticleId></ArticleIdList></Reference><Reference><Citation>Specific neuropilins expression in alveolar macrophages among tissue-specific macrophages. Aung NY, Ohe R, Meng H, Kabasawa T, Yang S, Kato T, Yamakawa M. PLoS One. 2016;11:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764655</ArticleId><ArticleId IdType="pubmed">26900851</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulmonary macrophages and SARS-Cov2 infection. Bain CC, Lucas CD, Rossi AG. Int Rev Cell Mol Biol. 2022;367:1&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8968207</ArticleId><ArticleId IdType="pubmed">35461655</ArticleId></ArticleIdList></Reference><Reference><Citation>Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Grant RA, Morales-Nebreda L, Markov NS, et al. Nature. 2021;590:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987233</ArticleId><ArticleId IdType="pubmed">33429418</ArticleId></ArticleIdList></Reference><Reference><Citation>Conservation and enhanced binding of SARS-CoV-2 Omicron Spike protein to coreceptor neuropilin-1 predicted by docking analysis. Baindara P, Roy D, Mandal SM, Schrum AG. Infect Dis Rep. 2022;14:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9024780</ArticleId><ArticleId IdType="pubmed">35447881</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor. Onabajo OO, Banday AR, Stanifer ML, et al. Nat Genet. 2020;52:1283&#x2013;1293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377523</ArticleId><ArticleId IdType="pubmed">33077916</ArticleId></ArticleIdList></Reference><Reference><Citation>From fetal to neonatal neuroimaging in TORCH infections: a pictorial review. Lucignani G, Guarnera A, Rossi-Espagnet MC, et al. Children (Basel) 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9406729</ArticleId><ArticleId IdType="pubmed">36010101</ArticleId></ArticleIdList></Reference><Reference><Citation>Interferons and proinflammatory cytokines in pregnancy and fetal development. Yockey LJ, Iwasaki A. Immunity. 2018;49:397&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6152841</ArticleId><ArticleId IdType="pubmed">30231982</ArticleId></ArticleIdList></Reference><Reference><Citation>p53/NF-kB Balance in SARS-CoV-2 Infection: From OMICs, Genomics and Pharmacogenomics Insights to Tailored Therapeutic Perspectives (COVIDomics) Milani D, Caruso L, Zauli E, et al. Front Pharmacol. 2022;13:871583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9201997</ArticleId><ArticleId IdType="pubmed">35721196</ArticleId></ArticleIdList></Reference><Reference><Citation>p53-independent roles of MDM2 in NF-&#x3ba;B signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Thomasova D, Mulay SR, Bruns H, Anders HJ. Neoplasia. 2012;14:1097&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540936</ArticleId><ArticleId IdType="pubmed">23308042</ArticleId></ArticleIdList></Reference><Reference><Citation>Potential of the miR-200 family as a target for developing anti-cancer therapeutics. Jo H, Shim K, Jeoung D. Int J Mol Sci. 2022;23</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9180509</ArticleId><ArticleId IdType="pubmed">35682560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes. Riani M, Le Jan S, Pl&#xe9;e J, et al. J Allergy Clin Immunol. 2017;139:863&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637385</ArticleId></ArticleIdList></Reference><Reference><Citation>CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin. Ichikawa A, Kuba K, Morita M, et al. Am J Respir Crit Care Med. 2013;187:65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3927876</ArticleId><ArticleId IdType="pubmed">23144331</ArticleId></ArticleIdList></Reference><Reference><Citation>CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. Jinquan T, Jing C, Jacobi HH, et al. J Immunol. 2000;165:1548&#x2013;1556.</Citation><ArticleIdList><ArticleId IdType="pubmed">10903763</ArticleId></ArticleIdList></Reference><Reference><Citation>The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. Neuroimmunomodulation. 2014;21:322&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">24642726</ArticleId></ArticleIdList></Reference><Reference><Citation>Evolution, Expression and Functional Analysis of CXCR3 in Neuronal and Cardiovascular Diseases: A Narrative Review. Satarkar D, Patra C. Front Cell Dev Biol. 2022;10:882017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9252580</ArticleId><ArticleId IdType="pubmed">35794867</ArticleId></ArticleIdList></Reference><Reference><Citation>The cytokine milieu of bullous pemphigoid: Current and novel therapeutic targets. Maglie R, Solimani F, Didona D, Pipit&#xf2; C, Antiga E, Di Zenzo G. Front Med (Lausanne) 2023;10:1128154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9939461</ArticleId><ArticleId IdType="pubmed">36814775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullous pemphigoid. Miyamoto D, Santi CG, Aoki V, Maruta CW. An Bras Dermatol. 2019;94:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6486083</ArticleId><ArticleId IdType="pubmed">31090818</ArticleId></ArticleIdList></Reference><Reference><Citation>Insights into the pathogenesis of bullous pemphigoid: the role of complement-independent mechanisms. Cole C, Vinay K, Borradori L, Amber KT. Front Immunol. 2022;13:912876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9300999</ArticleId><ArticleId IdType="pubmed">35874745</ArticleId></ArticleIdList></Reference><Reference><Citation>Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center. Afacan E, Edek YC, &#x130;lter N, G&#xfc;lekon A. Int J Dermatol. 2022;61:626&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">35080255</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report. Alshammari F, Abuzied Y, Korairi A, Alajlan M, Alzomia M, AlSheef M. Ann Med Surg (Lond) 2022;75:103420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8885466</ArticleId><ArticleId IdType="pubmed">35251600</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Maronese CA, Caproni M, Moltrasio C, et al. Front Med (Lausanne) 2022;9:841506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8918943</ArticleId><ArticleId IdType="pubmed">35295599</ArticleId></ArticleIdList></Reference><Reference><Citation>CD147-spike protein interaction in COVID-19: get the ball rolling with a novel receptor and therapeutic target. Behl T, Kaur I, Aleya L, et al. Sci Total Environ. 2022;808:152072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8634688</ArticleId><ArticleId IdType="pubmed">34863742</ArticleId></ArticleIdList></Reference><Reference><Citation>Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. Muramatsu T. J Biochem. 2016;159:481&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846773</ArticleId><ArticleId IdType="pubmed">26684586</ArticleId></ArticleIdList></Reference><Reference><Citation>Galectin-3 induces clustering of CD147 and integrin-&#x3b2;1 transmembrane glycoprotein receptors on the RPE cell surface. Priglinger CS, Szober CM, Priglinger SG, et al. PLoS One. 2013;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3726584</ArticleId><ArticleId IdType="pubmed">23922889</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3. Mauris J, Woodward AM, Cao Z, Panjwani N, Arg&#xfc;eso P. J Cell Sci. 2014;127:3141&#x2013;3148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095856</ArticleId><ArticleId IdType="pubmed">24829150</ArticleId></ArticleIdList></Reference><Reference><Citation>How, with whom and when: an overview of CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Grass GD, Toole BP. Biosci Rep. 2015;36:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4718507</ArticleId><ArticleId IdType="pubmed">26604323</ArticleId></ArticleIdList></Reference><Reference><Citation>The S1 Subunit of the SARS-CoV-2 Spike protein activates human monocytes to produce cytokines linked to COVID-19: relevance to galectin-3. Schroeder JT, Bieneman AP. Front Immunol. 2022;13:831763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8982143</ArticleId><ArticleId IdType="pubmed">35392091</ArticleId></ArticleIdList></Reference><Reference><Citation>CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Wang K, Chen W, Zhang Z, et al. Signal Transduct Target Ther. 2020;5:283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor. Shilts J, Crozier TW, Greenwood EJ, Lehner PJ, Wright GJ. Sci Rep. 2021;11:413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801465</ArticleId><ArticleId IdType="pubmed">33432067</ArticleId></ArticleIdList></Reference><Reference><Citation>Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. Chen Z, Mi L, Xu J, et al. J Infect Dis. 2005;191:755&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110046</ArticleId><ArticleId IdType="pubmed">15688292</ArticleId></ArticleIdList></Reference><Reference><Citation>in silico evaluation of cyclophilin inhibitors as potential treatment for SARS-CoV-2. Laurie K, Holcomb D, Kames J, Komar AA, DiCuccio M, Ibla JC, Kimchi-Sarfaty C. Open Forum Infect Dis. 2021;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083350</ArticleId><ArticleId IdType="pubmed">34109257</ArticleId></ArticleIdList></Reference><Reference><Citation>Expression of CD147 and cyclophilin A in kidneys of patients with COVID-19. Su H, Wan C, Wang ZD, et al. Clin J Am Soc Nephrol. 2021;16:618&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092067</ArticleId><ArticleId IdType="pubmed">33268502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Liu C, von Brunn A, Zhu D. Med Drug Discov. 2020;7:100056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364167</ArticleId><ArticleId IdType="pubmed">32835213</ArticleId></ArticleIdList></Reference><Reference><Citation>MMP-9/BDNF ratio predicts more severe COVID-19 outcomes. Savic G, Stevanovic I, Mihajlovic D, Jurisevic M, Gajovic N, Jovanovic I, Ninkovic M. Int J Med Sci. 2022;19:1903&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682503</ArticleId><ArticleId IdType="pubmed">36438922</ArticleId></ArticleIdList></Reference><Reference><Citation>Matrix metalloproteinases in health and disease in the times of COVID-19. Fernandez-Patron C, Hardy E. Biomolecules. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9138430</ArticleId><ArticleId IdType="pubmed">35625620</ArticleId></ArticleIdList></Reference><Reference><Citation>Metalloproteinase-dependent and TMPRSS2-independent cell surface entry pathway of SARS-CoV-2 requires the furin cleavage site and the S2 domain of spike protein. Yamamoto M, Gohda J, Kobayashi A, et al. mBio. 2022;13:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426510</ArticleId><ArticleId IdType="pubmed">35708281</ArticleId></ArticleIdList></Reference><Reference><Citation>Angiotensin II-induced MMP-2 activity and MMP-14 and basigin protein expression are mediated via the angiotensin II receptor type 1-mitogen-activated protein kinase 1 pathway in retinal pigment epithelium: implications for age-related macular degeneration. Pons M, Cousins SW, Alcazar O, Striker GE, Marin-Casta&#xf1;o ME. Am J Pathol. 2011;178:2665&#x2013;2681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124233</ArticleId><ArticleId IdType="pubmed">21641389</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. Veras FP, Pontelli MC, Silva CM, et al. J Exp Med. 2020;217</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil-induced liver injury and interactions between neutrophils and liver sinusoidal endothelial cells. Wang Y, Liu Y. Inflammation. 2021;44:1246&#x2013;1262.</Citation><ArticleIdList><ArticleId IdType="pubmed">33649876</ArticleId></ArticleIdList></Reference><Reference><Citation>NETosis and the immune system in COVID-19: mechanisms and potential treatments. Gillot C, Favresse J, Mullier F, Lecompte T, Dogn&#xe9; JM, Douxfils J. Front Pharmacol. 2021;12:708302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8376580</ArticleId><ArticleId IdType="pubmed">34421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophil extracellular traps induce human&#xa0;Th17 cells: effect of psoriasis-associated TRAF3IP2 genotype. Lambert S, Hambro CA, Johnston A, Stuart PE, Tsoi LC, Nair RP, Elder JT. J Invest Dermatol. 2019;139:1245&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092801</ArticleId><ArticleId IdType="pubmed">30528823</ArticleId></ArticleIdList></Reference><Reference><Citation>The amyloidoses: clinical features, diagnosis and treatment. Baker KR, Rice L. Methodist Debakey Cardiovasc J. 2012;8:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3487569</ArticleId><ArticleId IdType="pubmed">23227278</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 infection and vaccination and its relation to amyloidosis: what do we know currently? Leung WY, Wu HH, Floyd L, Ponnusamy A, Chinnadurai R. Vaccines (Basel) 2023;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10383215</ArticleId><ArticleId IdType="pubmed">37514955</ArticleId></ArticleIdList></Reference><Reference><Citation>The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Kell DB, Pretorius E. Biochem J. 2022;479:1653&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484810</ArticleId><ArticleId IdType="pubmed">36043493</ArticleId></ArticleIdList></Reference><Reference><Citation>Analysis of the autoimmune response against BP180 in patients with Alzheimer's disease. Wang YN, Hammers CM, Mao X, Jin HZ, Yuan J, Li L. Ann Transl Med. 2021;9:107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7867912</ArticleId><ArticleId IdType="pubmed">33569409</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteolytic cleavage of the SARS-CoV-2 Spike protein and the role of the novel S1/S2 site. Jaimes JA, Millet JK, Whittaker GR. iScience. 2020;23:101212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255728</ArticleId><ArticleId IdType="pubmed">32512386</ArticleId></ArticleIdList></Reference><Reference><Citation>ACE2-independent infection of T lymphocytes by SARS-CoV-2. Shen XR, Geng R, Li Q, et al. Signal Transduct Target Ther. 2022;7:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8914143</ArticleId><ArticleId IdType="pubmed">35277473</ArticleId></ArticleIdList></Reference><Reference><Citation>Myeloid-derived suppressor cells in COVID-19: the paradox of good. Grassi G, Notari S, Gili S, et al. Front Immunol. 2022;13:842949.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9092297</ArticleId><ArticleId IdType="pubmed">35572540</ArticleId></ArticleIdList></Reference><Reference><Citation>Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy. Kamran N, Chandran M, Lowenstein PR, Castro MG. Clin Immunol. 2018;189:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5400737</ArticleId><ArticleId IdType="pubmed">27777083</ArticleId></ArticleIdList></Reference><Reference><Citation>IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. Tobin RP, Jordan KR, Kapoor P, et al. Front Oncol. 2019;9:1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857649</ArticleId><ArticleId IdType="pubmed">31781510</ArticleId></ArticleIdList></Reference><Reference><Citation>Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. Gao FX, Wu RX, Shen MY, et al. iScience. 2022;25:105479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9625849</ArticleId><ArticleId IdType="pubmed">36338436</ArticleId></ArticleIdList></Reference><Reference><Citation>Neutrophils and lymphopenia, an unknown axis in severe COVID-19 disease. Pe&#xf1;aloza HF, Lee JS, Ray P. PLoS Pathog. 2021;17:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412274</ArticleId><ArticleId IdType="pubmed">34473802</ArticleId></ArticleIdList></Reference><Reference><Citation>Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Irrgang P, Gerling J, Kocher K, et al. Sci Immunol. 2023;8:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847566</ArticleId><ArticleId IdType="pubmed">36548397</ArticleId></ArticleIdList></Reference><Reference><Citation>IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. van de Veen W, Stanic B, Yaman G, et al. J Allergy Clin Immunol. 2013;131:1204&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">23453135</ArticleId></ArticleIdList></Reference><Reference><Citation>Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Science. 2007;317:1554&#x2013;1557.</Citation><ArticleIdList><ArticleId IdType="pubmed">17872445</ArticleId></ArticleIdList></Reference><Reference><Citation>A New Classification System for IgG4 Autoantibodies. Koneczny I. Front Immunol. 2018;9:97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5816565</ArticleId><ArticleId IdType="pubmed">29483905</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical significance of allergen-specific IgG4 in allergic diseases. Qin L, Tang LF, Cheng L, Wang HY. Front Immunol. 2022;13:1032909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648126</ArticleId><ArticleId IdType="pubmed">36389804</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypersensitivity may be involved in severe COVID-19. Tan C, Zheng X, Sun F, et al. Clin Exp Allergy. 2022;52:324&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652637</ArticleId><ArticleId IdType="pubmed">34570395</ArticleId></ArticleIdList></Reference><Reference><Citation>Does SARS-CoV-2 induce IgG4 synthesis to evade the immune system? Rubio-Casillas A, Redwan EM, Uversky VN. Biomolecules. 2023;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10526126</ArticleId><ArticleId IdType="pubmed">37759738</ArticleId></ArticleIdList></Reference><Reference><Citation>Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Kiszel P, S&#xed;k P, Mikl&#xf3;s J, Kajd&#xe1;csi E, Sinkovits G, Cervenak L, Proh&#xe1;szka Z. Sci Rep. 2023;13:13166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423719</ArticleId><ArticleId IdType="pubmed">37574522</ArticleId></ArticleIdList></Reference><Reference><Citation>The appearance of anti-spike receptor binding domain immunoglobulin G4 responses after repetitive immunization with messenger RNA-based COVID-19 vaccines. Yoshimura M, Sakamoto A, Ozuru R, et al. Int J Infect Dis. 2024;139:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">38029832</ArticleId></ArticleIdList></Reference><Reference><Citation>Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19. Adhikari B, Bednash JS, Horowitz JC, Rubinstein MP, Vlasova AN. Front Immunol. 2024;15:1325243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10883056</ArticleId><ArticleId IdType="pubmed">38390335</ArticleId></ArticleIdList></Reference><Reference><Citation>SARS-CoV-2 Spike 1 protein controls natural killer cell activation via the HLA-E/NKG2A pathway. Bortolotti D, Gentili V, Rizzo S, Rotola A, Rizzo R. Cells. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7563485</ArticleId><ArticleId IdType="pubmed">32859121</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating Spike protein detected in post-COVID-19 mRNA vaccine myocarditis. Yonker LM, Swank Z, Bartsch YC, et al. Circulation. 2023;147:867&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10010667</ArticleId><ArticleId IdType="pubmed">36597886</ArticleId></ArticleIdList></Reference><Reference><Citation>Circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Ogata AF, Cheng CA, Desjardins M, et al. Clin Infect Dis. 2022;74:715&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: possible molecular mechanisms. Brogna C, Cristoni S, Marino G, et al. Proteomics Clin Appl. 2023;17:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">37650258</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. J Virol. 2003;77:4911&#x2013;4927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC152117</ArticleId><ArticleId IdType="pubmed">12663797</ArticleId></ArticleIdList></Reference><Reference><Citation>Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. Streeck H, Brumme ZL, Anastario M, et al. PLoS Med. 2008;5:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2365971</ArticleId><ArticleId IdType="pubmed">18462013</ArticleId></ArticleIdList></Reference><Reference><Citation>Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. Bucks CM, Norton JA, Boesteanu AC, Mueller YM, Katsikis PD. J Immunol. 2009;182:6697&#x2013;6708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2923544</ArticleId><ArticleId IdType="pubmed">19454664</ArticleId></ArticleIdList></Reference><Reference><Citation>Dysfunctional state of T cells or exhaustion during chronic viral infections and COVID-19: a review. Mishra KP, Singh M, Saraswat D, Ganju L, Varshney R. Viral Immunol. 2022;35:284&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">35325564</ArticleId></ArticleIdList></Reference><Reference><Citation>A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19) Mohammed RN, Tamjidifar R, Rahman HS, et al. Cell Commun Signal. 2022;20:79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162381</ArticleId><ArticleId IdType="pubmed">35655192</ArticleId></ArticleIdList></Reference><Reference><Citation>Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients [PREPRINT] Benitez Fuentes JD, Mohamad KM, de Luna Aguilar A, et al. Res Sq. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9808030</ArticleId><ArticleId IdType="pubmed">36605446</ArticleId></ArticleIdList></Reference><Reference><Citation>Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Blackburn SD, Shin H, Haining WN, et al. Nat Immunol. 2009;10:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605166</ArticleId><ArticleId IdType="pubmed">19043418</ArticleId></ArticleIdList></Reference><Reference><Citation>Molecular and cellular insights into T cell exhaustion. Wherry EJ, Kurachi M. Nat Rev Immunol. 2015;15:486&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889009</ArticleId><ArticleId IdType="pubmed">26205583</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>